Rivaroxaban
| Grade | Pharmaceutical |
| Pharmacopoeia | BP, USP |
| CAS No. | 366789-02-8 |
| Product Name | Rivaroxaban |
| Chemical Name | 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide |
| Function | Active Pharmaceutical Ingredients (APIs) |
| Industrial Application | Pharmaceutical |
| Category | Anticoagulant |
General Description
Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. It is prescribed for deep vein thrombosis (DVT), which usually occurs in the leg, and pulmonary embolism (PE), which occurs in the lungs. It is also used to prevent blood clots in patients with atrial fibrillation and those undergoing hip or knee replacement surgery.
Physical Characteristics
| Molecular formula | C₁₉H₁₈ClN₃O₅S |
| Molecular weight | 435.88 |
| Appearance | White or off white, crystalline powder |
| Solubility | Soluble in DMSO, practically insoluble in ethanol |
| Water | Maximum 1.0% |
| Enantiomeric purity | Not less than 99.0% |
| Residue on ignition | Maximum 0.1% |
| Purity | Minimum 99.5% |
| Assay | 98.0% to 102.0% (anhydrous basis) |
| Storage | Preserve in tight, light-resistant containers at controlled room temperature. Keep away from heat and moist |